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Abstract
Objectives—The treatment goal in congenital adrenal hyperplasia (CAH) is to replace 
glucocorticoids while avoiding androgen excess and iatrogenic Cushing’ s syndrome. However, 
there is no consensus on how to monitor disease control. Our main objectives were to evaluate 
hormonal circadian rhythms and use these profiles to identify optimal monitoring times and novel 
disease biomarkers in CAH adults on intermediate- and long-acting glucocorticoids.
Design—This was an observational, cross-sectional study at the National Institutes of Health 
Clinical Center in 16 patients with classic CAH.
Methods—Twenty-four hour serum sampling for corticotropin (ACTH), 17-
hydroxyprogesterone (17OHP), androstenedione (A4), androsterone, dehydroepiandrosterone 
(DHEA), testosterone, progesterone and 24-hour urinary pdiol and 5?-pdiol was carried out. 
Bayesian spectral analysis and cosinor analysis were performed to detect circadian rhythmicity. 
The number of hours to minimal (TminAC) and maximal (TmaxAC) adrenocortical hormone levels 
after dose administration were calculated.
Results—A significant rhythm was confirmed for ACTH (r2 0.95;P<0.001), 17OHP (r2 0.70; 
P=0.003), androstenedione (r2 0.47;P=0.043), androsterone (r2 0.80;P<0.001), testosterone (r2 
0.47;P=0.042) and progesterone (r2 0.64;P=0.006). The mean (SD) TminAC and TmaxAC for 
17OHP and A4 were: morning prednisone [4.3(2.3) and 9.7(3.5) hours], evening prednisone 
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[4.5(2.0) and 10.3(2.4) hours], and daily dexamethasone [9.2(3.5) and 16.4(7.2) hours]. AUC0-24hr 
progesterone, androsterone and 24-hour urine pdiol were significantly related to 17OHP.
Conclusion—In CAH patients adrenal androgens exhibit circadian rhythms influenced by 
glucocorticoid replacement. Measurement of adrenocortical hormones and interpretation of results 
should take into account the type of glucocorticoid and time of dose administration. Progesterone 
and backdoor metabolites may provide alternative disease biomarkers.
Keywords
circadian rhythms; CAH; 17-hydroxyprogesterone; androstenedione; corticotropin; progesterone; 
androsterone
Introduction
Congenital adrenal hyperplasia is an autosomal recessive condition which in 95% of patients 
is caused by 21-hydroxylase deficiency, an enzyme of the cytochrome P450 family essential 
for cortisol and aldosterone biosynthesis 1. This enzyme defect results in cortisol deficiency, 
which by impaired negative feedback on the hypothalamic-pituitary-adrenal axis, stimulates 
ACTH synthesis. ACTH secretion is regulated by circadian input from the central clock in 
the suprachiasmatic nucleus and follows a circadian pattern with an early morning rise, 
reaching a peak in the morning on waking, and slowly declining towards an evening nadir 2. 
In untreated or most treated CAH patients this rhythm is maintained and adrenal androgens, 
which are also under the influence of ACTH, are released in a circadian pattern resulting in 
hyperandrogenism and its clinical consequences 3–5.
Patients with CAH suffer from multiple morbidities related to excess androgens or 
glucocorticoid over-replacement. Thus, the challenge for the endocrinologist is to achieve a 
balance between these two undesirable states. Endocrine Society guidelines have 
recommended the use of hydrocortisone in children whereas up to two-thirds of adults are 
commonly receiving intermediate and long-acting glucocorticoids 1, 6. A number of 
strategies have been suggested to help guide dose titration, such as measuring 17-
hydroxyprogesterone (17OHP) and androstenedione before the early morning 
hydrocortisone dose in an attempt to measure peak hormone levels 7, 8. No definite criteria 
exist as to what time in relation to dose administration this should be performed in patients 
on intermediate- and long-acting glucocorticoids. Synthetic glucocorticoids have diverse 
pharmacokinetic characteristics with wide inter-individual variability and unpredictable 
effects on rhythm parameters and hormone concentrations 9, 10, making it problematic for 
physicians to decide on dose changes when measuring random hormone levels.
We measured hormonal circadian rhythms of CAH patients on intermediate- and long-acting 
glucocorticoids. In addition to routinely measured hormones we analyzed profiles of 
progesterone, dehydroepiandrosterone (DHEA), the precursor to pregnanetriol, 5?-
pregnane-3?, 17?-diol-20-one (5?-pdiol), and the backdoor pathway metabolites 
androsterone (also a classic pathway product) and 5?-pregnane-3?, 17?-diol-20-one 
(pdiol) 11 (Figure 1). The use of multiple hormone levels at different time points provided us 
with a robust measurement of 24-hour hormone exposure as opposed to a single random 
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hormone concentration as usually performed in clinical care. Our goal was to evaluate 
hormonal diurnal rhythms in patients with CAH, which then allowed us to determine 
optimal monitoring time ranges for identifying hormonal suppression and escape from 
hormonal control, and explore novel disease biomarkers.
Patients and Methods
Study Patients
An observational, cross sectional study was carried out at the National Institutes of Health 
Clinical Center, Bethesda, MD. Sixteen patients with classic 21-hydroxylase deficiency (5 
simple virilizing; 11 salt wasting) participated. This 24-hour serial sampling study was 
performed as part of the baseline visit of two clinical trials investigating the use of circadian 
hydrocortisone replacement (www.clinicaltrials.gov identifier no. NCT01735617 and 
NCT01859312) and patients were receiving their usual at home medication regimen. The 
diagnosis of CAH was ascertained using medical records and hormonal tests and confirmed 
by genotype 12. Five patients were on a daily dexamethasone dose (dose range: 0.25mg – 
0.5mg, in hydrocortisone equivalent (x 80)7 9.6 – 21.3mg/m2/day). Four of these patients 
were taking dexamethasone in the evening whereas one patient was taking dexamethasone 
in the morning. Eleven patients were on twice daily prednisone (dose range: 2mg to 7.5mg 
(am), 2mg to 5mg (pm) in hydrocortisone equivalent (x 5)7: 12.0mg/m2/day – 33.7mg/m2/
day. All patients were on a stable glucocorticoid regimen for a three month minimum. Other 
inclusion criteria included age 18 years and over, plasma renin activity less than 1.5 times 
the upper normal range and a negative pregnancy test. Patients who were taking medications 
that induce hepatic enzymes or interfere with glucocorticoid metabolism, spironolactone, 
inhaled, oral or nasal glucocorticoids apart from treatment for CAH, or had taken estrogen-
containing oral contraceptive pill within 6 weeks of recruitment were excluded. Patients 
with clinical or biochemical evidence of hepatic, renal or psychiatric disease, were also 
excluded. The study was approved by the Eunice Kennedy Shriver National Institutes of 
Child Health and Development (NICHD) Institutional Review Board and all patients gave 
their written informed consent.
Study Design
All participants were admitted overnight and blood was sampled from an intravenous 
cannula every two hours (23:00h until 23:00h). Patients continued to take their usual 
medications during sampling. The following hormones were measured: ACTH, 
androstenedione, 17OHP, androsterone, DHEA, testosterone and progesterone. 
Glucocorticoid levels (dexamethasone, prednisolone) were also measured. In addition, a 24-
hour urine sample, timed from 23:00h on Day 1 to 23:00h on Day 2, was collected to 
measure the backdoor metabolite pdiol and the precursor to pregnanetriol, 5?-pdiol (Figure 
1).
Assays
Hormones were analyzed at the NIH Clinical Center (Bethesda, MD, USA) unless otherwise 
noted. Androstenedione, 17OHP, androsterone, DHEA, testosterone and progesterone were 
measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) 13, 14. Within-
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day CVs ranged from 2.4–9.5% and between-day CVs from 3.0–9.9%. An Agilent 6490 
triple-quadrupole mass spectrometer coupled with an Atmospheric Pressure Photoionization 
(APPI) source and Agilent 1200 Infinity series HPLC were used employing isotope dilution 
with deuterium labeled internal standard for each analyte. Instrument parameters were as 
follows: gas temperature 325°C, vaporizer 400°C, gas flow of 11 L/min, nebulizer 60psi, 
and capillary 4000V.
Urinary pdiol and 5?-pdiol were determined by LC-ESI-MS/MS (NICHD Biomedical Mass 
Spectrometry Facility, Bethesda, MD). Briefly, 1 mL aliquots of urine were treated with ?-
glucuronidase (Type VII-A, Sigma), followed by addition of an internal standard (13C(3) 17-
hydroxyprogesterone). Steroids were then isolated by solid-phase weak anion exchange 
using DPX-WAX tips (DPX-Labs), eluted with isopropanol/5% ammonium hydroxide, and 
dried by vacuum centrifugation. The dried samples were dissolved in 0.2 mL 
isopropanol:water (1:1) (v/v) and analyzed by LC/MS/MS, using an Agilent 6460 QQQ 
mass spectrometer. Steroids were separated by reversed phase chromatography using an 
Acquity UPLC BEH C18 (2.1 I.D. × 150 mm) column, and eluted with a linear gradient 
from 100% A (water/0.1% formic acid) to 30% B (isopropanol/0.1% formic acid). Pdiol and 
5?-pdiol concentrations were determined by an MRM assay. The precursor ion [MH – 
2(H2O)]+ (m/z 299) was selected and product ions 161, 147, 135 were followed. 
Concentrations were determined from peak ratios of the pdiol or 5?-pdiol to the internal 
standard and standard curves generated by the addition of steroid standards to a stripped 
urine matrix. A linear response was obtained for levels up to 1500 pmol/mL (correlation 
coefficient > 0.997). Sensitivity was approximately 1 pmol/mL for either pdiol or 5?-pdiol 
and between-day CVs were from 4–12%. The minimum concentration of pdiol and 5?–pdiol 
for CAH pati ents was 3 and 20 pmol/mL respectively (median pdiol = 230 pmol/mL and 
5?–pdiol = 1,600 pmol/mL). Total urinary excretion of pdiol and 5?-pdiol per 24 hr was 
calculated from steroid concentration and the 24 hr urine volume for each patient.
Plasma ACTH was measured using a chemiluminescence immunoassay on Siemens 
Immulite 2000 XPi analyzer (NIH Clinical Center) with sensitivity of 1.1 pmol/L, and intra- 
and inter-assay CVs 2.5% and 3.6% respectively. Dexamethasone and prednisolone were 
analyzed by LC-MS/MS (Mayo Medical Laboratories, Rochester, MN) with a sensitivity of 
2.5nmol/L and 2.8nmol/L, respectively. For prednisolone and dexamethasone intra-assay 
CV were 4.9% and 6.1% at 33 and 31nmol/l, respectively whereas inter-assay CV were 
8.6% and 9.3% at 324nmol/l and 8nmol/l. The following conversion values for normal 
ranges were used: ACTH (1.1 – 10.1pmol/L; pg/mL *0.22); 17OHP (0.4 – 5.3nmol/L; ng/
dL*0.0303 ); Androstenedione (0.6 – 6.1nmol/L; ng/dL*0.0349); Androsterone (0.7 – 
2.8nmol/L; ng/dL*0.0349); DHEA (0.8 – 20.8nmol/L; ng/dL*0.0347); Testosterone male 
(3.5 – 25.7nmol/L; ng/dL*0.0347); Testosterone female (0.3 – 2.5nmol/L; ng/dL*0.0347 ); 
Progesterone male (0.03 – 0.2nmol/L; ng/mL*3.18 ); Progesterone female (0.03 – 
64nmol/L; ng/mL*3.18).
Statistical Analyses
Descriptive analyses were performed using SPSS Version 19 (Chicago, IL) and Microsoft 
Excel 2010 (Redmond, WA). Baseline variables are presented as median and interquartile 
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(IQR) ranges as in the majority a normal distribution was not present. Correlation analysis 
was carried out using Spearman’ s rho and differences between groups were assessed using 
the non-parametric Mann Whitney test. Linear regression analysis was performed to assess 
the relationship between classic and backdoor pathway metabolites.
Hormonal profiles were analyzed to detect the presence of circadian rhythms using Matlab 
Version 8.2 (Mathworks, Natick, MA). We initially took an exploratory approach, using 
Bayesian spectral analysis 15, 16 and, by assuming a harmonic relationship between 
frequency components, examined the data for evidence of a circadian fundamental 
frequency and the presence of individual components; this allowed us to detect a circadian 
rhythm, and estimate the period and number of harmonics. Hormonal data was log-
transformed due to the lack of normality. A cosine curve (cosinor model), a mathematical-
statistical regression technique used in chronobiological analyses of circadian rhythms 17, 
was then fitted to the averaged log-converted (ln) 24-hour data for each hormone found to 
have a circadian rhythm. By fitting in a cosinor model we were able to both confirm 
statistical significance of the rhythm and derive r2, the percentage of the variance that can be 
explained by the model17, 18. By using a p-value of statistical significance one rejects or 
accepts the hypothesis that the amplitude is zero and a significant p-value ascertains a 
significant rhythm is present.
To demonstrate circadian changes we also designed concentration-time profiles for each 
hormone for patients on either dexamethasone or prednisone using geometric mean (SEM) 
at each time point. We then measured 8-hour and 24-hour hormonal exposure which we 
defined by a PK approach ( WinNonlin Professional V5.2.1 software Certara, Princeton, NJ, 
USA). The parameters included geometric mean (10th – 90th percentiles) 8-hourly/24-hourly 
AUC (23:00h – 07:00h; 07:00h – 15:00h; 15:00h – 23:00h, 23:00h – 23:00h). To reduce 
heterogeneity, one patient receiving morning dexamethasone was evaluated separately. 
Two-tailed tests were performed and P-value < 0.05 was considered statistically significant.
Defining hormonal monitoring times
Circadian hormonal profiles provided robust measurements to help define optimal 
monitoring time ranges dependent on type and time of glucocorticoid administration. Two 
time parameters were used: 1) TminAC, the number of hours from dose administration to the 
lowest adrenocortical (AC) hormone level; 2) TmaxAC, the number of hours from dose 
administration to the maximal AC hormone level reached after the hormone escaped control. 
In some patients in whom hormone levels were above target ranges prior to dose 
administration and remained above these defined ranges after dosing, that is control was not 
achieved, TmaxAC was taken as the maximal concentration subsequent to a drop in hormone 
levels post dose administration. For individual variables, hormonal control was defined as: 
ACTH 1.1–15.2pmol/L(1.5 the upper limit of normal range), 17OHP 1.5–36nmol/L 7, 19 and 
normal range for androstenedione 0.6–6.1nmol/L, androsterone 0.7–2.8nmol/L, DHEA 0.8–
20.8nmol/L, testosterone (males 3.5–25.7nmol/L, females 0.3–2.5nmol/L) and progesterone 
(males 0.03–0.2nmol/L, females 0.03–64nmol/L). Overall disease control was based on 
androstenedione being within the normal range. Hormonal concentrations for routinely 
measured hormones at TminAC and TmaxAC were recorded.
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Results
Sixteen adult patients (6 women) with classic CAH participated, with median (IQR) age 23 
(20 – 42) years, weight 70.9 (57.5 – 95.4) kg and BMI 25.9 (22.5 – 32.5) kg/m2. Based on 
early morning 07:00h androstenedione, 8 (50%) patients were in poor disease control 29 
(SD 28)nmol/L. In males n=3, the androstenedione concentration was 42 (SD 37)nmol/L 
whilst in females n=5, this was 21 (SD 21)nmol/L. Eight patients had acceptable adrenal 
hormone levels 4 (SD 2)nmol/LIn males n=7, the androstenedione concentration was 4 (SD 
2)nmol/L whilst in females n=1, this was 4nmol/L. Based on 17:00h levels 10 (62.5%) 
patients had elevated androstenedione [17 (SD 12)nmol/L; males n=4, 19 (SD 9)nmol/L; 
females n=6, 16 (SD 14)nmol/L] (Supplementary Table 1). Eleven patients were on 
prednisone twice daily at median (10th – 90th percentiles) 08:00h (07:00h – 10:00h) and 
21:00h (19:00h – 23:00h) whereas four patients were taking dexamethasone in the evening 
at a median (10th – 90th percentiles) time of 22:00h (21:18h – 22:42h). One patient taking 
dexamethasone 0.375mg in the morning at 08:00h had normal hormonal control throughout 
most of the 24 hours.
Circadian rhythm analysis
All hormones except DHEA displayed evidence of circadian rhythm with remarkable 
consistency given the small sample size and inter-individual variation (Supplementary Table 
1). A cosinor model, fitted to the averaged 24-hour data of all patients, resulted in a 
significant sinusoidal curve for ACTH (r2 0.95; P<0.001) (2 harmonics) and 17OHP (r2 
0.70; P=0.003), androstenedione (r2 0.47; P=0.043), androsterone (r2 0.80; P<0.001), 
testosterone (r2 0.47; P=0.042) and progesterone (r2 0.64; P=0.006) (all one harmonic). The 
presence of a rhythm was not related to gender or type of glucocorticoid. To support these 
findings 8-hourly hormonal AUCs indicate higher hormonal exposure in the morning and 
early afternoon with decreasing levels thereafter (Table 1). Androsterone showed higher 
17:00h than 07:00h levels (IQR) (Supplementary Table 1) suggesting an inverted rhythm but 
this was not confirmed when estimating 8 hourly AUCs (Table 1). Concentration-time 
profiles for all hormones revealed variable hormonal responses to drug levels (Figure 2).
Establishing hormonal monitoring times
For patients on prednisone, the time to the lowest and peak hormone concentrations 
following morning and evening doses were remarkably similar across the majority of 
adrenocortical hormones (Table 2). Maximal levels occurred approximately 10 hours 
following dose, while the lowest values occurred approximately 4 to 5 hours following dose. 
Time for measurement of peak 17OHP and androstenedione, the typical biomarkers of 
disease control, best corresponded to [mean (SD) TmaxAC 9.7 (3.5) hours] after the morning 
dose and [mean (SD) TmaxAC 10.3 (2.4) hours] for the evening dose, whereas monitoring 
for hormonal suppression corresponded to [mean (SD) TminAC 4.3 (2.3) hours] for the 
morning dose and [mean (SD) TminAC 4.5 (2.0) hours] for the evening dose. In support of 
these findings, these time-points correlated (P<0.001) with pre and post 8-hourly AUCs 
(data not shown). In a sub-analysis exploring whether TmaxAC and TminAC in patients on 
prednisone varied in the different sexes these were in general similar with no significant 
differences (Supplementary Table 2).
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The time to lowest hormone concentrations and time to peak levels varied across the 
different adrenocortical hormones with once daily dexamethasone (Table 3). Time for 
measurement of 17OHP and androstenedione best corresponded to [mean (SD) TminAC 9.2 
(3.5) hours] and [mean (SD) TmaxAC 16.4 (7.2) hours] for dexamethasone.
Hormonal concentrations at these time points (TminAC vs TmaxAC) show significant 
differences for 17OHP (median 6.4 vs 67.6nmol/L; P=0.005), and androstenedione (median 
4.6 vs 9.5nmol/L; P=0.046) and no difference for testosterone (males median 9.3 vs 
11.8nmol/L; P=0.31; females median 1.3 vs 1.8nmol/L; P=0.15).
Exploring hormonal inter-relationships to identify novel disease biomarkers
One of the hormones that was analyzed in our study and is not routinely measured was 
progesterone. AUC(0-24hr) Progesterone significantly correlated with ACTH and 17OHP in 
both males and females, whereas in males these relationships were stronger and 
progesterone was also associated with androstenedione (Table 4, Supplementary Figure 1). 
Progesterone AUC0-24hr significantly correlated with backdoor metabolites (pdiol: females, 
rho=0.83, P=0.042; males, rho=0.87, P=0.002; serum androsterone AUC0-24hr: females, 
rho=1.0, P=0.01; males, rho=0.714, P=0.047). DHEA showed no relationship with ACTH, 
17OHP, androstenedione or any of the measured backdoor metabolites. 47% of patients had 
undetectable DHEA levels throughout the 24 hours.
Twenty-four hour urine pdiol, a backdoor pathway metabolite, serum androsterone, a 
product of both classic and backdoor pathways, and 5?-pdiol, a precursor of pregnanetriol, 
were significantly correlated with ACTH, 17OHP and androstenedione (Figure 3a, Table 4). 
Twenty-four hour urine pdiol (Median: 1848 vs 150nmol /24 hrs; P=0.004), 5?-pdiol 
(Median: 20481 vs 2643nmol /24hrs; P=0.011) and androsterone AUC0-24hr (Median: 229 
vs 75nmol/L; P=0.039) were significantly higher in patients with poor disease control 
(Figure 3b). Pdiol positively predicted androstenedione (unstandardized coefficient B=0.45 
95%CI 0.22 – 0.68; P=0.001) and 17OHP (unstandardized coefficient B=0.89 95%CI 0.63 – 
1.15; P<0.001) by linear regression.
Discussion
Our comprehensive hormonal analysis of adult patients with CAH reveals intact diurnal 
rhythms of multiple hormones and fluctuating androgen excess throughout the day that may 
not be detected with routine random single hormonal measurements. The androgen excess 
commonly experienced by patients with CAH resulted from both the classic and backdoor 
pathways to androgen production, albeit driven by the circadian secretion of ACTH. 
Twenty-four hour serial sampling allowed us to estimate when escape from hormonal 
suppression most commonly occurred and to evaluate this in relation to glucocorticoid 
administration. To our knowledge this is the most detailed study to date evaluating optimal 
monitoring times in patients on intermediate and long-acting glucocorticoids and the only 
study to also include backdoor pathway steroid metabolites.
In our study, detailed pharmacokinetic (PK) modelling revealed that maximal hormone 
levels in patients on morning and evening prednisone occur 10 hours after dose 
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administration and 16 hours following dexamethasone. In addition, lowest levels 
corresponding to maximal suppression occurs around 4 to 5 hours after prednisone and 9 
hours after a daily dexamethasone dose. Significant differences were observed between 
these highest and lowest levels of 17OHP and androstenedione, highlighting the importance 
of the timing of hormonal evaluation. Furthermore, we found that serum progesterone and 
androsterone and 24-hour urinary pdiol and 5?-pdiol correlated well with routinely 
monitored hormones and could be alternative markers of disease control. These findings 
provide insight into the importance of taking into consideration the type of glucocorticoid 
and the time of dose administration when monitoring hormone levels and also suggest that 
in poorly controlled CAH patients, both the classic and backdoor pathways are similarly 
activated.
The management of CAH changes throughout life. Although, the majority of children with 
CAH are treated with short-acting hydrocortisone 1, a significant number of CAH adults are 
treated with longer-acting glucocorticoids such as prednisone, prednisolone or 
dexamethasone 19, 20. These medications are often used for convenience because they can be 
dosed once or twice daily or to optimise compliance. Long- and intermediate-acting 
glucocorticoids have shown better adrenocortical suppression compared to 
hydrocortisone 21, 22, although they may increase risk of metabolic complications such as 
insulin resistance 19 and osteoporosis 23. Our data reveal that androgen suppression may be 
transient even for long- and intermediate-acting glucocorticoids with wide inter-individual 
variability. Prednisone is an inactive synthetic analogue of cortisone, and post-absorption is 
rapidly converted to biologically active prednisolone by hepatic 11-beta hydroxysteroid 
dehydrogenase Type 1. Although it is recognised that the biological half-life of prednisolone 
is approximately 18 – 36 hours 24, and the serum half-life is around 3 to 4 hours 25, 26, the 
biological half-life for corticosterone suppression has been shown to be 6.2 hours 27; 
Similarly, dexamethasone has a biological half-life of 36 – 54 hours 24, a serum half-life of 
around 4 to 5 hours and a biological half-life for corticosterone suppression of 7 hours 27. 
The corticosterone suppression data from Meikle et al 27 could explain why many of our 
patients on prednisone experienced maximal 17OHP and androstenedione within 10 hours 
following dose administration and patients on dexamethasone within 16 hours. 
Dexamethasone concentrations were detected in the circulation for around 10 hours. Our 
data also suggest that some patients receiving once daily dexamethasone could potentially 
benefit from twice daily dexamethasone though this might increase the risk for adverse 
metabolic effects. Other studies investigating monitoring times for hydrocortisone have 
shown a rapid fall in 17OHP levels after the morning hydrocortisone dose and early morning 
laboratory evaluation is generally suggested for patients receiving hydrocortisone 22, 28.
In most untreated patients, 17OHP and sex steroids maintain their circadian rhythms 3 and 
the circadian rhythm of 17OHP has been shown to develop as early as 3 months of age 29. 
Our analysis of 24-hour concentration-time profiles for androstenedione and 17OHP 
indicate that patients on long-acting glucocorticoids maintain hormonal rhythms and exhibit 
wide hormonal fluctuations. Interestingly, irrespective of a low glucocorticoid state, in some 
instances there was a decrease in 17OHP and androgen levels in the evening during the 
quiescent phase; an effect most likely related to circadian regulation of the endogenous 
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timing system by the central clock in the suprachiasmatic nucleus. Thus, hormonal 
disturbances may only be appreciated when measuring multiple hormone samples during the 
day. Unfortunately this type of research based analysis may be too intensive, laborious and 
costly to be carried out as part of daily clinical management. To circumvent this problem we 
attempted to define the most suitable time to measure hormone levels related to poor disease 
control, this dependent on time of dose and glucocorticoid formulation. This may be an 
alternative strategy especially as some clinicians do measure adrenal androgens during other 
times of the day such as late in the afternoon 30. Our opinion is that aiming to measure 
maximal hormone levels is most useful in clinical management, corresponding to evaluation 
in the early morning for night time prednisone, or late afternoon for morning prednisone or 
night time dexamethasone. We also emphasize that hormone levels taken at recommended 
time points should not preclude a full clinical assessment of the patient. Management 
decisions should take all clinical features and biochemical data into consideration.
Comprehensive steroid panels were evaluated. DHEA was mostly suppressed or within 
normal range even when disease was uncontrolled, confirming that DHEA is not a useful 
biomarker in CAH. In addition, DHEA levels did not correlate with any of the other 
measured hormones. Low DHEA has previously been described in patients with classic 
CAH 31, 32. Our data support the notion that DHEA is not solely regulated by ACTH in 
CAH patients, but low levels may be due to abnormal adrenal gland development as patients 
with 21-hydroxylase deficiency have been shown to have lack of zonation with extensive 
intermingling of adrenocortical and adrenomedullary cells 7, 33. Low intra-adrenal cortisol in 
CAH patients also may result in low DHEA production 31, 34.
Conversely progesterone may be useful in the management of CAH. In CAH, an increase in 
ACTH stimulation presumably drives the production of progesterone; this is supported by 
the significant correlation between progesterone and ACTH in our study. Much is unknown 
about progesterone in CAH. However, high progesterone levels could contribute to female 
infertility 35. In a case-control study of 16 women with classic CAH, those patients with a 
low LH pulse amplitude and frequency had higher progesterone levels and worse hormonal 
control than those with LH pulsatility similar to normal controls 36. Further studies 
investigating the relevance of high progesterone in CAH and its impact on fertility are 
needed.
An intriguing alternative pathway to androgen production is the backdoor pathway, which 
produces the most potent androgen, dihydrotestosterone (DHT), without the intermediary 
androstenedione or testosterone. 11, 37. Kamrath et al 11 found that androgen biosynthesis via 
the backdoor pathway is active throughout postnatal life, with possibly less backdoor 
pathway contribution to androgenic steroid production post adrenarche 38. Prior studies 
suggest that backdoor pathway androgen production increases in adults with CAH as control 
of androgen excess deteriorates 39. We mostly found a proportional increase in classic and 
backdoor pathway metabolites in adults as disease control deteriorates, albeit in a small 
sample size. The relationship between clinical features and backdoor pathway metabolites, 
together with the use of these hormones as markers of disease status, requires further 
investigation.
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Limiting factors in our study include the use of different doses of glucocorticoids that were 
administered at different times. Furthermore, a small number of patients were on 
dexamethasone. With regards to identifying minimal hormone levels or more specifically 
the maximal suppression following medication (TminAC), we did not account for the clock-
induced physiological drop in hormones, and this should be considered. In addition TminAC 
after evening prednisone suggests monitoring during very early morning which would be 
impractical in clinical practice though possibly useful to investigators in the research setting.
Our study is unique in that we obtained detailed 24-hour circadian profiles of common and 
uncommon biomarkers of androgen excess in patients with classic CAH allowing us to 
approximate ideal monitoring times post dose administration. Achieving optimal metabolic 
control is difficult in CAH and we found that laboratory evaluation is best performed in 
relation to medication timing. Backdoor pathway metabolites and progesterone are 
alternative biomarkers of disease control and may be useful in the management of CAH 
patients. Future studies should investigate the association between these steroids and clinical 
features of hyperandrogenism. Our findings provide useful information regarding the 
management of the adult patient with CAH and thus may help guide future clinical practice.
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Figure 1. Pathway of adrenal steroidogenesis
Normally, the principal route for adrenocortical androgen production is via the classic 
pathway (solid line arrows). In 21-hydroxylase deficiency, large amounts of 17OHP are 
converted to androstenedione via this classic pathway and these are the common biomarkers 
used in CAH to estimate disease control. Accumulating 17OHP can also be converted to 
pdione via an alternative route termed the backdoor pathway (dotted arrows). Androsterone 
is produced by both the classic and backdoor pathways. The end product for both pathways 
is ultimately dihydrotestosterone (DHT), the most potent androgen receptor agonist.
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Figure 2. Serum Hormonal profiles for exogenous glucocorticoids and CAH-related hormones
A) Eleven patients (six males; five females) receiving twice daily prednisone experienced 
hormonal escape mainly in the early morning for ACTH, androstenedione, androsterone and 
progesterone (males). 17OHP levels were higher in the morning but mainly remained within 
the desired range. In some patients a spontaneous reduction in hormone levels occurs before 
the evening dose.
B) Four patients (3 males; one female) receiving nocturnal dexamethasone had escape of 
most hormones including ACTH, 17OHP, androstenedione, androsterone and progesterone 
in the afternoon. Dotted segment of dexamethasone concentration-time profile (between 
13:00h and 21:00h) represents undetectable levels
Geometric mean (SEM) is shown for prednisolone and dexamethasone and all other 
hormones. Horizontal dotted lines indicate normal ranges or optimal hormonal control. Only 
one female was taking dexamethasone.
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Figure 3. 
Figure 3A. Hormonal Inter-Relationships for pdiol, 5?-pdiol and androsterone
Correlations between backdoor pathway 24 hour urine pdiol (i – iii), 5?-pdiol (iv – vi) and 
AUC(0-24hr) androsterone (vii-ix) with major serum biomarkers
Figure 3B. Pdiol, 5?-pdiol and androsterone levels in CAH
Box and whisker plots demonstrate higher concentrations of pdiol, 5?-pdiol and 
androsterone in patients with classic CAH. Significantly higher levels are evident in patients 
with poor control. Poor control defined as 07:00h androstenedione level >6.0nmol/L.
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Table 1
24-Hour and 8-Hourly Hormonal Exposure in patients with Classic CAH on treatment
Geometric mean (10th to 90th 
percentiles)
AUC (24 hours) [23:00 
– 23:00]
AUC (23:00 – 07:00) AUC (07:00 – 15:00) AUC (15:00 – 23:00)
ACTH (pmol/L.hr) 257 (38 – 1227) 45 (8 – 383) 106 (11 – 631) 82 (15 – 417)
17OHP (nmol/L.hr) 633 (19 – 7113) 122 (5 – 2066) 265 (8 – 3784) 199 (5 – 1700)
Androstenedione (nmol/L.hr) 179 (30 – 1081) 51 (11 – 325) 65 (10 – 453) 59 (9 – 303)
Androsterone (nmol/L.hr) 121 (44 – 478) 33 (11 – 130) 43 (13 – 192) 42 (14 – 157)
DHEA (nmol/L.hr) 42 (10 – 730) 13 (3 – 115) 16 (3 – 344) 12 (3 – 301)
Testosterone (males) (nmol/L.hr) 321 (127 – 2037) 109 (23 – 1536) 105 (52 – 248) 90 (36 – 252)
Testosterone (females) (nmol/L.hr) 40 (22 – 131) 12 (6 – 41) 14 (7 – 42) 14 (8 – 47)
Progesterone (males) (nmol/L.hr) 17.0 (1.2 – 543.8) 4.4 (0.3 – 197.2) 6.5 (0.2 – 286.2) 4.3 (0.2 – 184.1)
Progesterone (females) (nmol/L.hr) 58.8 (13.4 – 1329.2) 6.6 (0.2 – 321.2) 23.2 (2.3 – 537.4) 22.2 (6.4 – 470.6)
AUC, area under the curve
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Table 2
Target Monitoring Times Following Twice Daily Prednisone in 11 Patients with Classic CAH
Morning Dose Evening Dose
TminAC (h)1 TmaxAC (h)1 TminAC (h)1 TmaxAC (h)1
ACTH 4.5 (1.3) 11.0 (2.5) 3.2 (1.5) 10.9 (2.0)
17OHP 4.7 (2.4) 9.7 (3.5) 4.9 (1.8) 10.7 (2.0)
Androstenedione 3.8 (2.2) 9.6 (3.6) 4.1 (2.1) 10.0 (2.8)
Androsterone 7.4 (3.1) 10.2 (3.2) 4.2 (2.6) 8.2 (3.5)
DHEA 3.4 (4.1) 12.7 (1.6) 2.5 (3.8) 10.1 (2.2)
Testosterone 6.0 (4.4) 11.5 (2.7) 3.8 (1.3) 11.0 (1.5)
Progesterone 4.0 (1.9) 10.2 (3.3) 4.0 (2.5) 11.2 (2.0)
Prednisone (Dose Range – HC equiv: 12mg/m2/day – 33.7mg/m2/day)
1
Mean (SD)
TminAC, the number of hours from dose administration to minimal adrenocortical (AC) hormone level; TmaxAC, the number of hours from dose 
administration to the maximal AC hormone level
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Table 3
Target Monitoring Times Following Once Daily Dexamethasone in 5 patients with Classic CAH
Once Daily Dose
TminAC (h)1 TmaxAC (h)1
ACTH 5.8 (1.9) 20.2 (4.4)
17OHP 9.4 (1.8) 17.4 (6.5)
Androstenedione 9.0 (4.8) 15.4 (8.4)
Androsterone 6.2 (2.2) 17.4 (8.7)
DHEA 3.4 (2.9) 21.4 (3.6)
Testosterone 3.8 (2.4) 20.6 (7.6)
Progesterone 6.2 (1.9) 11.8 (7.6)
Dexamethasone (Dose Range - HC equiv: 9.6 – 21.3mg/m2/day)
1
Mean (SD)
TminAC, the number of hours from dose administration to minimal adrenocortical (AC) hormone level; TmaxAC, the number of hours from dose 
administration to the maximal AC hormone level
Eur J Endocrinol. Author manuscript; available in PMC 2016 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Debono et al. Page 20
Table 4
Correlation between routinely measured biomarkers and other classic and backdoor pathway metabolites
Biomarkers ACTH Co-efficient (P-value) 1 17OHP Co-efficient (P-value) 1 Androstenedione Co-efficient (P-value) 1
Serum Steroids
Androsterone2 0.63 (0.02) 0.75 (≤0.01) 0.79 (<0.001)
DHEA −0.09 0.31 0.17
Testosterone – Male −0.60 −0.53 −0.42
Testosterone – Female 0.83 (0.04) 0.71 0.77
Progesterone – Male 0.73 (0.03) 0.98 (<0.001) 0.70 (0.04)
Progesterone – Female 0.89 (0.02) 0.83 (0.04) 0.71
Urinary Steroids
Pdiol 0.62 (≤0.01) 0.85 (<0.001) 0.84 (<0.001)
5?-pdiol 0.68 (≤0.01) 0.88 (<0.001) 0.77 (<0.001)
Correlations based on AUC0-24hr (serum) or 24-hour urine collection.
1
P-values > 0.05 not shown.
2Androsterone produced by both classic and backdoor pathways
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